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ABSTRACT
Mutations in the gene for telomerase reverse tran-
scriptase (hTERT) are associated with diseases
including dyskeratosis congenita, aplastic anemia,
pulmonary fibrosis and cancer. Understanding the
molecular basis of these telomerase-associated
diseases requires dependable quantitative measure-
ments of telomerase enzyme activity. Furthermore,
recent findings that the human POT1-TPP1 chromo-
some end-binding protein complex stimulates tel-
omerase activity and processivity provide incentive
for testing variant telomerases in the presence of
these factors. In the present work, we compare
multiple disease-associated hTERT variants recons-
tituted with the RNA subunit hTR in two systems
(rabbit reticulocyte lysates and human cell lines)
with respect to telomerase enzymatic activity,
processivity and activation by telomere proteins.
Surprisingly, many of the previously reported
disease-associated hTERT alleles give near-normal
telomerase enzyme activity. It is possible that a
small deficit in telomerase activity is sufficient to
cause telomere shortening over many years.
Alternatively, mutations may perturb functions such
as the recruitment of telomerase to telomeres, which
are essential in vivo but not revealed by simple
enzyme assays.
INTRODUCTION
Complete replication of chromosome ends in most
human cells requires telomerase. Telomerase is a
ribonucleoprotein (RNP) enzyme, consisting of a
template-containing RNA subunit known as TR, TER
or TERC (1), a reverse transcriptase subunit TERT (2,3)
and multiple accessory proteins including dyskerin (4,5).
In the absence of telomerase, chromosomes undergo pro-
gressive telomere shortening as seen in human somatic
cells that do not express TERT and as documented in
budding and ﬁssion yeast mutants and in mice with TR
or TERT gene knockouts (6).
Continued proliferation of human cells requires main-
tenance of telomere length by telomerase or by alternative
mechanisms. The causal relationship between telomere
shortening and replicative senescence was established by
ectopic expression of telomerase reverse transcriptase
(hTERT) in human somatic cells (7). Insufﬁcient telomer-
ase activity can cause telomere shortening, decreased cell
proliferation and tissue degeneration. The rare inherited
disorder dyskeratosis congenita (characterized by defects
in highly proliferative tissues such as skin and bone
marrow) has been traced to insufﬁcient telomerase
activity due to mutations in the dyskerin protein subunit
(8), the telomerase RNA (9) and TERT (10), or in
telomere components such as TINF2 and RTEL1
(11–13). Recently, other diseases including idiopathic pul-
monary ﬁbrosis and aplastic anemia have been associated
with telomerase deﬁciency (14). Telomerase deﬁciency also
contributes to multiple forms of cancer, presumably
because short telomeres lead to genome instability which
contributes to oncogenesis (15–18).
Heterozygotes with one defective allele of hTERT or
hTR are unable to maintain highly proliferative tissues
because of haploinsufﬁciency (10,14,19). Interestingly, a
related situation occurs in yeast, where telomerase RNA
is haploinsufﬁcient for telomere length maintenance (20).
Non-synonymous single-nucleotide mutations in the
hTERT gene occur at 5% frequency; 44 different non-
synonymous mutations have been identiﬁed in the NHLBI
Exome Sequencing Project (http://evs.gs.washington.edu)
as of January 2013, and this number will grow quickly
as the cost of genome sequencing continues to plummet.
Therefore, knowing which of these amino acid
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changes has phenotypic consequences will only grow in
importance.
Most of the human genetic studies have assessed the
activity of variant telomerases by reconstitution of
hTERT and hTR in rabbit reticulocyte lysates (RRLs)
or by transient transfection of genes encoding mutant tel-
omerase components into tissue culture cells. Telomerase
activity is then measured either by a PCR-based assay
called the Telomeric Repeat Ampliﬁcation Protocol
(TRAP) assay or by direct analysis of extension of a telo-
meric DNA primer. These methods have been recently
reviewed (4). Here, we use the direct enzyme assay
because it provides excellent quantiﬁcation and informa-
tion about the step in the enzymatic cycle that is defective
while avoiding potential PCR artifacts (21).
In past studies, the direct telomerase assay has been
carried out with synthetic DNA oligonucleotides of telo-
meric sequence (TTAGGG repeats) as primers. However,
genetic and biochemical evidence indicates that the single-
stranded DNA at chromosome ends in vivo is bound by a
protein heterodimer, POT1-TPP1. POT1-TPP1 stimulates
telomerase processivity (22), and this higher processivity
would appear to be required for one or two rounds of
telomerase engagement to achieve the in vivo lengthening
of 50 nt per cell cycle (23). One hTERT mutant, G100V,
has been found to be insensitive to POT1-TPP1 stimula-
tion (24); therefore, it seems important to assess whether
any of the disease-associated alleles might also have such a
defect.
Here, we perform a comparative analysis of 24 disease-
associated hTERT variants using the direct telomerase
enzyme assay. These non-synonymous mutations span
most of the 1132-amino-acid TERT protein, including
the TEN domain that anchors the DNA primer, the TR
RNA-binding domain, the RT catalytic domain that re-
sembles that of retroviral and retrotransposon RTs, and
the C-terminal extension (Figure 1a). Our goals are to
provide quantitative information about the effects of
single amino acid substitutions on telomerase activity
and processivity, to compare telomerase assembled
in vitro with the enzyme assembled in human cells and
to test the mutants for their ability to respond to POT1-
TPP1 activation. Unanticipated ﬁndings suggest a reinter-
pretation of some disease-associated hTERT variants
described previously.
MATERIALS AND METHODS
Mutagenesis
Mutations in hTERT were made using the QuickChange
II XL site-directed mutagenesis kit (Stratagene) with
primers designed as described (25), and all mutated
genes were completely sequenced. All primers were
purchased from IDT.
RRL reconstitution of telomerase
C-terminal HA-tagged human TERT was expressed from
phTERT-HA2. N-terminal 3FLAG-tagged human
TERT was expressed from phTERT-3FLAG, and hTR
was expressed from phTR using the TnT quick-coupled
transcription/translation system (Promega) as previously
described (24). Each 500 ml reaction contained 400 ml of
TnT quick mix, 8 ml of 35S-methionine (Perkin-Elmer),
10 ml of PCR enhancer (Promega), 10 ml of 1mM methio-
nine, 10 mg of supercoiled hTERT plasmid and 10 mg of
puriﬁed hTR RNA (transcribed from Fok I-cut phTR
plasmid DNA), and water to a total of 500 ml. After incu-
bation for 2 h at 30C, the reconstituted telomerase
complex was afﬁnity-puriﬁed for 2 h at 4C on anti-HA
F7 agarose beads (Santa Cruz Biotechnologies) or anti-
FLAG agarose beads (Sigma). The beads were washed
with 1 human telomerase buffer with 30% glycerol four
times and then resuspended in the same solution. The
quantity of 35S-hTERT was determined by liquid scintilla-
tion counting and used to normalize the telomerase
activities. Unused beads were quick-frozen in liquid
nitrogen and stored at 80C.
Reconstitution of telomerase in human cells
HEK293T or VA13 cells (both from ATCC) were transi-
ently transfected with plasmids expressing N-terminal
3FLAG-tagged human TERT (WT or mutants) and
human telomerase RNA (hTR). Parent plasmids were a
gift of J. Lingner (EPFL, Lausanne) (26), and we added
sequences encoding epitope tags and mutations. Cells were
grown for 2 days, and extracts were made using CHAPS
lysis buffer (26). Telomerase was puriﬁed using anti-
FLAG agarose beads and the beads used in telomerase
activity assays. Unused beads were quick-frozen in
liquid nitrogen and stored at 80C and retained substan-
tial activity for at least 1 year.
Telomerase activity assays
Human telomerase complexes reconstituted in RRLs or
human cell lines were immunopuriﬁed and analyzed by
direct telomerase assays (24). Each reaction mixture
(20 ml) contained 1 human telomerase assay buffer
(50mM Tris–HCl at pH 8.0, 50mM KCl, 1mM MgCl2,
5mM 2-mercaptoethanol, 1mM spermidine), 1.0 mM telo-
meric DNA primer a5 (TTAGGGTTAGGGTTAGCG
TTA, where the underlined mutation serves to position
POT1-TPP1 on the 50 end of the primer), 0.5mM
dATP, 0.5mM dTTP, 2.92 mM dGTP and 0.33mM
32P-dGTP (3000Ci/mmol, 1Ci=37GBq), with 6 ml of
immunopuriﬁed telomerase complex. Reactions contain-
ing 0.5mM POT1 or 0.5 mM TPP1 or both contained
0.05 mM primer instead of 1.0 mM primer a5. Reactions
were incubated for 1 h at 30C, then stopped by adding
100 ml of 3.6M NH4OAc containing 20 mg of glycogen.
Samples were precipitated by addition of 500 ml of
ethanol for 1 h at 80C, then centrifuged for 15min at
4C. Pellets were washed with 70% ethanol and resus-
pended in 10 ml of water followed by 10 ml of 2 loading
buffer (94% formamide, 0.1 TBE, 0.1% bromophenol
blue, 0.1% xylene cyanol). Samples were denatured by
boiling and then loaded onto a 10% polyacrylamide/
7 M urea/1 TBE denaturing gel for electrophoresis.
Gels were dried and quantiﬁed by using a
PhosphorImager (GE Healthcare).
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Figure 1. Disease-associated mutations in hTERT have wide-ranging effects on telomerase activity in the RRL assay. (a) Map of the hTERT protein
showing location of disease-associated alleles studied here. Directly below, amino acid sequence motifs; DAT, mutations in these regions dissociate
the in vivo and in vitro activities of telomerase. TEN, RBD, RT and CTE, protein structural domains. (b) Expression of variant hTERT proteins in
the RRL system (Top panel, SDS–PAGE and autoradiography) and direct telomerase assays (Bottom panel, PAGE and autoradiography). (c)
Activity of mutant telomerases relative to WT. (d) Processivity calculated by the linear regression method.
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Western blots
Proteins were separated by SDS–PAGE on 4–12% poly-
acrylamide Bis Tris Glycine gels (Novex, NP0321). The
anti-FLAG antibody (Sigma A8592) is horseradish
peroxidase (HRP) conjugated; therefore, it required no
secondary antibody. In some cases, protein levels were
conﬁrmed by western blots using the anti-TERT
antibody Abcam Ab32020, a rabbit monoclonal
antibody raised against the 20 C-terminal amino acids of
hTERT (Supplementary Figure S1). We found Ab32020
to have good speciﬁcity for hTERT; the signal depended
on protein overexpression, and the presence of one amino
acid substitution in the F1127L mutant eliminated the
signal (Supplementary Figure S1).
Protein expression and puriﬁcation
Proteins hPOT1 and hTPP1-N (amino acids 89–334) were
expressed and puriﬁed as reported previously (22,27).
Concentrations were determined by the Bio-Rad Protein
Assay, based on the Bradford method; hPOT1 was typic-
ally 40–50% active, as determined by quantitative DNA-
binding titrations.
Processivity quantiﬁcation
The number of counts in each lane of a telomerase activity
gel was determined using PhosphorImager scanning and
ImageQuant software (28). The graph of ln F versus
repeat number n was ﬁt with a linear regression, and
processivity=0.693/slope. The ﬁrst repeat was not
included in the ﬁt because telomerase synthesizes one or
two repeats before synthesis is linear. Alternatively, in the
‘> 15 repeats method’, relative processivity was estimated
as the counts from repeat 15 and above divided by the
total number of counts in the lane (29).
RESULTS
The two systems most commonly used for expression and
assembly of recombinant telomerase are RRLs and
cultured human cells. Whether these systems are more-
or-less interchangeable has been tested in only a few
cases (30–32). The two systems are likely to differ in the
pathway of telomerase assembly, in the type and quantity
of molecular chaperones that facilitate RNP formation
and in the availability of accessory proteins such as
dyskerin and Nop10. These differences could have differ-
ential effects on different hTERT mutants, with the
human cell system presumably more likely to approximate
the in vivo situation. One goal of the present work is to
determine the degree of concordance between telomerase
assays performed in these two systems.
Assay of telomerase core enzymes assembled in RRLs
From the practical standpoint of the telomerase re-
searcher, the RRL system has the advantage that 35S-me-
thionine can be incorporated into the hTERT during
translation. This provides a straightforward means of
normalizing activity measurements to the amount of
hTERT present in the assay. (Normalizing instead to the
amount of bound hTR would obscure the effect of
RNA-binding deﬁciencies; a mutant with 1% RNA-
binding activity, when normalized to hTR, would show
100% activity.) The quality of the protein expressed can
be readily determined by SDS–PAGE; as seen in the top
panel of Figure 1b, most hTERT alleles were expressed
with similar efﬁciency and gave homogeneous full-length
proteins (the exception was Y772C, which always showed
a shorter product as well as the full-length protein; not
shown).
Representative telomerase assays are shown in
Figure 1b, bottom panel. A telomeric oligonucleotide
primer is extended in the presence of 32P-dGTP; the tel-
omerase enzyme stalls or dissociates when it reaches the
end of the TR RNA template, producing the 6 nt repeats
characteristic of telomerase. The reproducibility of the
assay was assessed by performing triplicate reactions
(Samples 1, 2 and 3) on each of two biological replicates
(RRL Translation 1 and 2). Reactions performed inde-
pendently by two different researchers using two different
epitope tags on the TERT gave similar results
(Supplementary Figure S2). Although we sometimes add
a radiolabeled oligonucleotide before DNA precipitation
as a loading control, this controls for only one of many
steps that impact the precision of the assays. Therefore, in
this study, we instead performed replicate assays to assess
reproducibility. Occasional loss of a DNA pellet (12th
lane in Figure 1b) is apparent even without a loading
control.
‘Activity’ was measured as the total amount of
radiolabeled nucleotide incorporated into the primer in a
1 h reaction (Figure 1c). ‘Processivity’, the average number
of DNA repeats synthesized after a single primer-binding
event, was determined by analyzing the distribution of
products as described in ‘Materials and Methods’ section
(Figure 1d); qualitatively, enzymes with wild-type or
higher processivity produced a full ladder of extension
products, whereas others [K570N and R865H; see also
(34)] were defective in processivity, synthesizing mostly
one repeat (Figure 1b). Enzymes with extremely low
activity (such as G682D) could not be assessed for
processivity. The quantiﬁcation is summarized in Table 1.
All hTERT genes were subjected to complete DNA
sequence analysis by the Sanger method to conﬁrm the
presence of the mutation and the absence of any other
change. Nevertheless, in cases where the activity of an
allele seemed to differ from that reported in the literature,
we sought additional evidence that our site-speciﬁc muta-
genesis did not produce a second mutation. This was ac-
complished by using oligonucleotide-directed mutagenesis
to revert the mutant allele back to wild-type, a procedure
that would retain any hypothetical mutations away from
the targeted site (Supplementary Figure S3). The reversion
to wild-type activity provided additional conﬁdence that
loss of activity was due only to the disease-associated
mutation.
Assay of telomerase assembled in cultured human cells
This approach starts with overexpression of both hTR and
hTERT in human embryonic kidney (HEK) 293T cells
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(26,40). An N-terminal 3FLAG tag on hTERT gave a
strong and unobstructed signal on western blots
(Figure 2a), allowing the amount of hTERT protein in
the extract to be measured and adjusted such that each
assay contained an equal amount of hTERT. The
3FLAG tag also allowed immunopuriﬁcation of tel-
omerase on antibody-coated beads, which were then
used in a direct assay for telomerase activity with a telo-
meric oligonucleotide primer and 32P-dGTP (Figure 2b).
Activity and processivity for telomerases containing
disease-associated hTERT mutations were quantiﬁed,
and the results are summarized in Table 1.
A number of control experiments provided conﬁdence
that the observed differences in activity were due to the
hTERT mutations rather than variability in the assay.
First, the activity obtained in independent transfections of
the HEK293T cells was as reproducible as that seen with
replicate assays of the same extract (Figure 2b). Second, the
amounts of hTERT and hTR plasmids transfected into cells
were optimized, and small ﬂuctuations in the amount of
DNA transfected would have little effect on the measured
telomerase activity (Supplementary Figure S4). Third, the
measured activity was a linear function of the amount of
telomerase used (Supplementary Figure S5), a fundamental
requirement for studies of enzyme activity. Finally, the 1-h
reaction time was approximately in the linear
range (Supplementary Figure S6a and b); the fall-off in
incorporation at longer times was due to slow inactivation
of the enzyme, as determined by enzyme pre-incubation
studies (Supplementary Figure S6c and d). Based on these
data, wewould recommend a 20 or 30min standard time for
future studies.
The reproducibility of the data, as determined by SEM,
was similar for the HEK cell assays and the RRL assays.
The key question, then, is whether these two systems give
equivalent values of telomerase activity. A direct compari-
son is shown in Figure 3. For most alleles, the two systems
gave the same activity measurement, but in four cases, the
differences were statistically signiﬁcant (P< 0.0001).
These results serve to emphasize that the information
one really wants to know is the telomerase activity in
the relevant human tissue, and measurements of telomer-
ase assembled in human cells or in RRLs are imperfect
surrogates for this information.
To begin to assess whether the choice of human cell line
might affect telomerase activity, we performed a more
limited analysis transfecting hTR and various hTERT
alleles into WI38 VA13/2RA cells, a telomerase-negative
cell line that maintains telomeres by alternative lengthen-
ing of telomeres (41) [for a typical example of prior work,
see (36)]. Telomerase activities of the hTERT alleles in the
VA13 cells were consistent with those obtained in the
(a)
(b) WT S191T K570N R865H S948R V694M A1062T
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Figure 2. Disease-associated variants of hTERT expressed in HEK293T cells with hTR and analyzed by the direct assay. (a) Western blot with an
anti-hTERT antibody showing uniform expression of the alleles in triplicate. It is not known whether the minor breakdown of S948R hTERT
contributes to its reduced activity or enhanced processivity. (b) Direct telomerase assays.
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HEK cells (Supplementary Figure S7). There were,
however, some quantitative differences; for example,
V694M had a relative activity of 0.16±0.01 in VA13
cells compared with 0.10±0.02 in HEK cells. We
conclude that if it were sufﬁcient to group hTERT alleles
into three categories—essentially wild-type activity, sub-
stantially reduced activity (10–50%) and loss of function
(<10%)—then HEK cells, VA13 cells and RRLs give
equivalent results. However, at the present time, we do
not know whether these broad categories are sufﬁcient
or whether instead a 10 or 20% reduction in telomerase
activity might be important over a human lifespan.
hTERT mutants respond to POT1-TPP1 activation
The human telomere DNA-binding protein heterodimer
POT1-TPP1 stimulates telomerase processivity (22) and
recruitment to telomeres (29,42). Because the telomerase
at chromosome ends is likely to be associated with these
proteins in vivo, we tested the alleles in the presence
of saturating amounts of POT1-TPP1. Representative
telomerase enzyme assays are shown in Figure 4.
Quantiﬁcation revealed that all of the disease-associated
alleles that retained some activity were activated by POT1-
TPP1 (e.g. S948R, A1062T, F1127L and WT all showed
>7-fold processivity enhancement relative to no POT1-
TPP1 when the data in Figure 4 were analyzed by the
>15 repeats method). The R865H processivity mutant
clearly had processivity restored in the presence of
POT1-TPP1, but the low level made quantiﬁcation difﬁ-
cult. The extremely low activity of mutant K902N was
slightly increased but not rescued by POT1-TPP1. We
questioned whether the high-molecular-weight ‘smear’
near the top of the gel for active alleles really represented
telomerase products; however, extending the electro-
phoresis time to resolve these products revealed that
they represented a continuation of the 6 nt repeat ladder
(Supplementary Figure S8); therefore, they were included
in the quantiﬁcation. In conclusion, although the previ-
ously described G100V mutant of hTERT shows that
a POT1-TPP1-insensitive mutant is possible, none of
the disease-associated mutants tested here had this
property.
DISCUSSION
Insufﬁcient telomerase activity in highly proliferative tissues
causes telomere shortening, which can lead to decreased cell
proliferation and tissue degeneration or to genome instabil-
ity and cancer. Because of haploinsufﬁciency, even a single
codon substitution in one of the two alleles of hTERT can
contribute to disease. Thus, the question of which hTERT
sequence variants are hypomorphic is of great interest.
Previous studies each compared a small number of telomer-
ases reconstituted with hTERT proteins containing disease-
associated amino acid substitutions. Here, we present a
side-by-side analysis of a much larger set of disease-
associated variants. Our quantitative analysis of the
activities of 24 mutant telomerases gives new insights into
the precision and accuracy of such measurements, and it
reveals that many reported disease-associated mutations
have unexpectedly little effect on telomerase enzyme
activity per se.
Many disease-associated hTERT variants do not show
much decrease in telomerase enzyme activity
Many published articles have shown that an hTERT
variant is associated with dyskeratosis congenita or
another disease of stem cell deﬁciency and that the
subjects harboring the mutant gene have short telomeres
(14,43). The reasonable expectation is then that this
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T
- P T P/
T
- P T P/
T
- P T P/
T
- P T P/
T
- P T P/
T
1
2
3
4
5
6
7
8
9
10
12
14
16
20
24
30
Repeats
+2
+4
40
+2+4 Variant
Figure 4. Telomerases assembled from WT and mutant hTERT
assayed for activity in the presence and absence of telomere proteins.
Telomerase was reconstituted in RRLs and activity measured by the
standard assay () or in the presence of 500 nM POT1 (P), 500 nM
TPP1 (T) and 500 nM of each protein (P/T), concentrations high
enough to saturate the oligonucleotide primer (22). +2 and +4,
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Figure 3. Comparison of relative activities of telomerases expressed in
HEK cells (H) and RRLs (R). Error bars=SEM, n=4–18.
**Statistically signiﬁcant differences (P< 0.0001).
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hTERT mutant will be defective in telomerase activity,
which has been reported in many cases (14,43). We were
therefore surprised to ﬁnd that 10 of the 19 disease-
associated alleles tested did not exhibit substantial loss
of function of reconstituted telomerase (i.e. they had
61–100% of wild-type activity; as described later in the
text, an allele with 60% activity is expected to give 80%
overall activity when ‘averaged’ with the wild-type allele in
a heterozygous individual). Robart and Collins (34) and
Zhong et al. (42) also noted a lack of correlation between
disease association and decreased telomerase activity for a
limited set of alleles.
The lack of the expected correlation could have a
number of explanations. First, a modest deﬁcit in telomer-
ase activity (10–20% decrease) could be sufﬁcient to cause
telomere shortening for a period of many years. This
might be especially apparent in individuals who inherited
short telomeres. Second, the activities of hTERT alleles
in vivo may not be well represented by the simple in vitro
enzyme assays. For example, an hTERT mutation could
inhibit telomerase recruitment to telomeres in vivo but
have no effect on enzyme activity per se (42,44). Third,
an individual’s genetic background would be expected to
enhance (or suppress) the effect of hTERT mutations.
Candidate genes include those for transcription factors
such as c-Myc and Ets2, which drive transcription of the
hTERT gene (45), and those for telomere proteins
including TPP1, which contributes to telomerase recruit-
ment to telomeres and telomere elongation (22,29,42).
Finally, some hTERT variants reported as disease-
associated may not be causally related to the disease.
Comparison of methods for measuring activity
Two different methods of reconstituting the telomerase—
transcription/translation in RRLs and transfection of
plasmids into human cells—generally gave the same
results. However, in the cases of V694M and S948R
(and also the non-processive K570N), the SEM was
small enough that we conclude that the two systems give
different average values. There are many potential differ-
ences between the two systems—the assembly pathway,
the availability of molecular chaperones, the concentra-
tion of telomerase-accessory proteins such as dyskerin
and Nop10 and post-transcriptional and post-transla-
tional modiﬁcations—and it is not surprising that these
could differentially affect the assembly of mutant and
wild-type telomerase RNP complexes. If it were sufﬁcient
to know whether a telomerase mutation has little or no
effect (>50% activity), is hypomorphic (10–50% active) or
is essentially inactivating (<10% activity), then it appears
that one can use either RRLs or human cells and achieve
the same result, in agreement with the more limited com-
parisons done previously (30–32). As described earlier in
the text, however, it is currently unknown whether these
broad categories are sufﬁcient to predict telomerase
haploinsufﬁciency.
In stark contrast to the general agreement between tel-
omerase reconstituted in vitro and in human cells, only
about half of our direct assay measurements agreed
even qualitatively with published TRAP assay values.
Differences in cell lines are unlikely to explain the
discrepancies because in our hands, multiple alleles gave
similar activity in HEK cells as in the VA13 cells used in
many previous reports. The discordance was mostly in the
direction of the direct measurements showing greater
activity. This was especially apparent with the P65A,
A202T and V1090M alleles, which gave 61–88% of wild-
type activity in our direct assays and <1% by TRAP. Our
primer extension assays use a low dGTP concentration
relative to that used in TRAP, which could result in a
high TRAP/direct assay ratio for a mutant defective in
nucleotide binding. Such a situation is opposite to what
we observe; therefore, it cannot explain the low TRAP
assay values. We have no basis for concluding whether
false-negative TRAP measurements are revealing general
challenges with using this assay (4) or are speciﬁc to a
particular study.
The direct assay revealed that the K570N mutation
destroys telomerase processivity. We considered that the
discrepancy between our activity measurements (in the
20–40% range) and the TRAP assay (<1%) could be
explained by short products not being effectively ampliﬁed
in the TRAP assay. However, the R865H mutant also has
low processivity (34), almost as low as K570N (see
Table 1), and in that case, our direct assay of activity
matched the published TRAP values. In any case, these
comparisons do serve to point out one obvious advantage
of the direct assay: it gives information about both activity
and processivity, whereas the ‘ladder’ of products
observed by TRAP is produced by PCR and is not
related to enzyme processivity in any simple way (4,46).
Activity in heterozygotes
Because most disease-associated alleles of hTERT or of
hTR occur in heterozygotes, a number of researchers
have co-assembled mutant and wild-type alleles to test
for dominant negative inhibition. In most cases, they
observed activity that was intermediate between that of
the individual alleles, indicating that the disease pheno-
type is due to haploinsufﬁciency rather than dominant
negative inhibition (10,18,19,33,37,38,47,48). The one ex-
ception is the report by Sauerwald et al. (49), in which the
catalytically inactive DN allele was found to poison the
activity of a co-assembled wild-type subunit. We
coexpressed the K570N, R865H, K902N and S948R
alleles with wild-type hTERT in HEK293T cells and
found the activity to be the average of the wild-type and
mutant alleles (A.J.Z. and T.R.C., unpublished data).
Taken together, these data support the conclusion that
the activity of a variant allele plus a wild-type allele in a
heterozygote can in most cases be calculated from the
measured activity of the variant allele when present in
pure form (i.e. a mutant with 10% activity would be pre-
dicted to give (10+100)/2=55% activity in the context of
a heterozygote).
Activity in presence of telomere proteins
The ﬁndings that the human telomere end-binding protein
complex, POT1-TPP1, stimulates telomerase activity and
processivity (22) and that the interaction between TPP1
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and telomerase is essential for activity in vivo (29,42)
would appear to mandate assaying all mutant hTERTs
in the presence of POT1-TPP1. However, all active tel-
omerases tested here were stimulated by POT1-TPP1.
The G100V mutant of hTERT (an engineered mutant,
not found to be disease associated) is not stimulated by
POT1-TPP1 (24), and some disease-associated alleles not
studied here may be defective in this interaction (42).
Prediction of mutant hTERT activity in silico
Given the slow and tedious process of testing hTERT
variants for activity by the direct telomerase enzyme
assay, the ﬁeld would beneﬁt greatly from methods for
predicting activity computationally. For some of the
mutated sites, such as R865 and K902, inspection of the
Tribolium TERT crystal structure (Supplementary Figure
S9) shows close proximity to the active site and suggests
that amino acid substitutions should be deleterious, and
this is the case (activity levels of 18 and 2%, respectively).
However, only the experimental approach could reveal the
processivity defect in R865H, and in any case, the lack of
structural information about the human telomerase RNP
prevents this approach from being generally useful. The
PolyPhen-2 software tool predicts the probability that an
amino acid substitution will be damaging to the structure
and function of a human protein using physical and evo-
lutionary (comparative sequence) criteria (50). For
about half of the variants, the PolyPhen-2 prediction
agrees qualitatively with our activity measurements
(Supplementary Figure S10). For most of the other
variants, PolyPhen-2 is too pessimistic (i.e. it overesti-
mates the effect of the mutation); alternatively, for one
case (G682D) PolyPhen-2 predicts that the mutation
should be benign when it is deleterious. Thus, although
it should eventually be possible to predict the effects of
single amino acid substitutions in silico, experimental
measurements are likely to be required for the foreseeable
future.
Concluding remarks
There is a general sense in the human telomerase ﬁeld that
the most common sequence variants are polymorphisms
without phenotypic consequence, whereas the disease-
causing variants are de novo mutations that are rare in
the population. The four non-synonymous single-nucleo-
tide variants found with highest frequency in the NHBLI
Exome Sequencing Project (S191T, H412Y, A1062T and
A279T; 10–275 occurrences/12 000 genes) all have high
enzymatic activity in our study, and all of the deleterious
variants are rare in the population (0 or 1 occurrence in
the Exome Sequencing Project). Thus, although more data
on allele frequencies are needed before making a ﬁrm con-
clusion, our work supports the prevailing generalization
that most disease-causing hTERTmutations will be rare in
the population.
SUPPLEMENTARY DATA
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